Jessica Wilson
Family · Montgomery, ALNPI 1518528298
Payments from drug & device makers
Across 276 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$741
- AstraZeneca$740
- GSK$607
- Novo Nordisk$520
- Pfizer$366
- Lilly USA, LLC$338
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,13699%
- Education$661%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 45 | $741 |
| AstraZeneca | 35 | $740 |
| GSK | 31 | $607 |
| Novo Nordisk | 32 | $520 |
| Pfizer | 22 | $366 |
| Lilly USA, LLC | 20 | $338 |
| Corium, LLC | 11 | $212 |
| Amgen(2 entities) | 10 | $201 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $190 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $153 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $134 |
| Almatica Pharma LLC | 5 | $118 |
| Astellas Pharma US Inc | 3 | $103 |
| Otsuka America Pharmaceutical, Inc. | 5 | $93 |
| Phathom Pharmaceuticals, Inc. | 5 | $84 |
| Exact Sciences | 4 | $68 |
| Mylan Specialty L.p. | 3 | $55 |
| Axsome Therapeutics, Inc. | 2 | $49 |
| Neurocrine Biosciences, Inc. | 2 | $49 |
| Intuitive Surgical | 1 | $45 |
| Abbott | 2 | $41 |
| Collegium Pharmaceutical, Inc. | 2 | $39 |
| Lundbeck LLC | 2 | $35 |
| Tris Pharma Inc | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Boehringer Ingelheim | 2 | $30 |
| Shield Therapeutics Inc | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Bayer | 1 | $19 |
| IBSA Pharma Inc. | 1 | $17 |
| Merck | 1 | $17 |
| Medtronic | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
How this compares
$5,202 in reported general payments places this provider in the 90th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 59 | $82,670 |
| EliquisApixaban | 68 | $68,156 |
| MounjaroTirzepatide | 39 | $51,964 |
| TrulicityDulaglutide | 28 | $48,202 |
| JanuviaSitagliptin Phosphate | 44 | $39,012 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $37,710 |
| LinzessLinaclotide | 35 | $29,955 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $23,106 |
| Nurtec OdtRimegepant Sulfate | 12 | $21,461 |
| FarxigaDapagliflozin Propanediol | 24 | $16,859 |
| XareltoRivaroxaban | 13 | $15,633 |
| JardianceEmpagliflozin | 14 | $12,447 |
| RexultiBrexpiprazole | 12 | $11,537 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 18 | $10,862 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 30 | $9,803 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $338 | $100,16667 claims |
| PfizerEliquis, Nurtec Odt | $366 | $89,61780 claims |
| Novo NordiskOzempic | $520 | $82,67059 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $607 | $65,78679 claims |
| MerckJanuvia, Janumet Xr | $17 | $49,87462 claims |
| AbbVieLinzess, Synthroid | $741 | $32,16767 claims |
| AstraZenecaFarxiga, Symbicort | $740 | $20,47938 claims |
| Johnson & JohnsonXarelto | $19 | $15,63313 claims |
| Boehringer IngelheimJardiance | $30 | $12,44714 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $93 | $11,53712 claims |
| Astellas Pharma US IncMyrbetriq | $103 | $8,48911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,415 family providers in Alabama.
Other family in Montgomery
- Leigh LunaMontgomery$69K
- Brandy YoungMontgomery$27K
- Angela RaybornMontgomery$22K
- Ashley MorrowMontgomery$21K
- Jackie ShumateMontgomery$19K
- Katrina Jones HarrisMontgomery$18K
- Brittney BarberMontgomery$12K
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.